AU2016238437B2 - Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide - Google Patents

Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide Download PDF

Info

Publication number
AU2016238437B2
AU2016238437B2 AU2016238437A AU2016238437A AU2016238437B2 AU 2016238437 B2 AU2016238437 B2 AU 2016238437B2 AU 2016238437 A AU2016238437 A AU 2016238437A AU 2016238437 A AU2016238437 A AU 2016238437A AU 2016238437 B2 AU2016238437 B2 AU 2016238437B2
Authority
AU
Australia
Prior art keywords
methyl
particles
amino
citric acid
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016238437A
Other languages
English (en)
Other versions
AU2016238437A1 (en
Inventor
Nicole Buschmann
Robin Alec Fairhurst
Pascal Furet
Bo Han
Thomas Knoepfel
Catherine Leblanc
Lv LIAO
Robert Mah
Franck Mallet
Julie MARTZ
Can Wang
Jing XIONG
Xianglin ZHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2016238437A1 publication Critical patent/AU2016238437A1/en
Application granted granted Critical
Publication of AU2016238437B2 publication Critical patent/AU2016238437B2/en
Priority to AU2019200936A priority Critical patent/AU2019200936A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016238437A 2015-03-25 2016-03-23 Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide Active AU2016238437B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019200936A AU2019200936A1 (en) 2015-03-25 2019-02-07 Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7- formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8- naphthyridine-1(2H)-carboxamide

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015000202 2015-03-25
CNPCT/CN2015/000202 2015-03-25
PCT/IB2016/051633 WO2016151500A1 (en) 2015-03-25 2016-03-23 Particles of n-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2h)-carboxamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200936A Division AU2019200936A1 (en) 2015-03-25 2019-02-07 Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7- formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8- naphthyridine-1(2H)-carboxamide

Publications (2)

Publication Number Publication Date
AU2016238437A1 AU2016238437A1 (en) 2017-08-17
AU2016238437B2 true AU2016238437B2 (en) 2018-11-08

Family

ID=55637404

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016238437A Active AU2016238437B2 (en) 2015-03-25 2016-03-23 Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
AU2019200936A Abandoned AU2019200936A1 (en) 2015-03-25 2019-02-07 Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7- formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8- naphthyridine-1(2H)-carboxamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019200936A Abandoned AU2019200936A1 (en) 2015-03-25 2019-02-07 Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7- formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8- naphthyridine-1(2H)-carboxamide

Country Status (14)

Country Link
US (1) US9802917B2 (https=)
EP (1) EP3274349B1 (https=)
JP (1) JP6696995B2 (https=)
KR (1) KR102606643B1 (https=)
CN (1) CN107406448B (https=)
AR (1) AR104060A1 (https=)
AU (2) AU2016238437B2 (https=)
CA (1) CA2977326C (https=)
ES (1) ES2803028T3 (https=)
MX (1) MX2017012293A (https=)
PL (1) PL3274349T3 (https=)
RU (1) RU2720456C2 (https=)
TW (1) TWI699206B (https=)
WO (1) WO2016151500A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6585167B2 (ja) * 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
CN113234072B (zh) * 2016-05-20 2022-11-04 江苏豪森药业集团有限公司 Fgfr4抑制剂、其制备方法和应用
CN107619388A (zh) 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CA3075720A1 (en) * 2017-10-02 2019-04-11 Novartis Ag Method for preparing a pharmaceutical product
CN110234649B (zh) * 2017-10-31 2021-10-15 江苏豪森药业集团有限公司 Fgfr4抑制剂的盐、晶体、制备方法及其用途
WO2019085860A1 (zh) * 2017-10-31 2019-05-09 江苏豪森药业集团有限公司 Fgfr4抑制剂晶型及其制备方法
CN109745321B (zh) * 2017-11-08 2022-04-29 上海翰森生物医药科技有限公司 包含fgfr4抑制剂的药物组合物
AU2020298246A1 (en) * 2019-06-21 2022-01-27 Terns Pharmaceuticals Inc. Compounds for inhibiting FGFR4

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015059668A1 (en) * 2013-10-25 2015-04-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
CA2261633A1 (en) 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
ES2241192T3 (es) 1997-12-17 2005-10-16 MERCK & CO., INC. (A NEW JERSEY CORP.) Antagonistas del receptor de integrina.
AR015514A1 (es) 1998-02-10 2001-05-02 Novartis Ag Compuesto de amida, proceso para su preparacion y composicion farmaceutica que lo contiene
EP1218336A2 (en) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
JPWO2003068753A1 (ja) 2002-02-14 2005-06-02 小野薬品工業株式会社 Ｎ−カルバモイル窒素含有縮合環化合物およびその化合物を有効成分として含有する薬剤
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
AU2003303231A1 (en) 2002-12-20 2004-07-14 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1613322A4 (en) 2003-04-11 2008-08-13 Taigen Biotechnology Co Ltd AMINOQUINOLINE COMPOUNDS
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
CN101223167B (zh) 2005-07-15 2011-08-31 弗·哈夫曼-拉罗切有限公司 杂芳基稠合的环状胺
BRPI0620408B8 (pt) 2005-12-21 2021-05-25 Novartis Ag derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica
EP1976528A2 (en) 2005-12-29 2008-10-08 Janssen Pharmaceutica, N.V. Prokineticin 2 receptor antagonists
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
CA2679268A1 (en) 2007-03-09 2008-09-18 Novartis Ag Treatment of melanoma
WO2009079008A1 (en) 2007-12-19 2009-06-25 Yangbo Feng Benzopyrans and analogs as rho kinase inhibitors
US20110172217A1 (en) 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
RU2561109C2 (ru) 2008-12-19 2015-08-20 Дженентек, Инк. Соединения и способы применения
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
CA2761009A1 (en) 2009-05-04 2010-11-11 Plexxikon, Inc. Compounds and methods for inhibition of renin, and indications therefor
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
CN102596916B (zh) 2009-10-30 2015-06-17 诺瓦提斯公司 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲的n-氧化物
KR20120130104A (ko) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Ｇｐｒ119 작동약
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
AP2013007153A0 (en) 2011-03-18 2013-09-30 Lupin Ltd Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US20150290235A1 (en) 2012-11-23 2015-10-15 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP3019491A4 (en) 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc KINASEHEMMER FOR THE TREATMENT OF DISEASES
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
MX378288B (es) 2013-10-18 2025-03-10 Eisai R&D Man Co Ltd Inhibidores de pirimidina del fgfr4.
CA2928042C (en) 2013-10-25 2022-05-10 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015059668A1 (en) * 2013-10-25 2015-04-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

Also Published As

Publication number Publication date
TWI699206B (zh) 2020-07-21
RU2017133243A3 (https=) 2019-07-29
EP3274349B1 (en) 2020-04-22
AU2019200936A1 (en) 2019-02-28
AU2016238437A1 (en) 2017-08-17
CA2977326A1 (en) 2016-09-29
AR104060A1 (es) 2017-06-21
BR112017016991A2 (pt) 2018-04-10
CN107406448B (zh) 2021-03-09
KR20170129758A (ko) 2017-11-27
EP3274349A1 (en) 2018-01-31
TW201641106A (zh) 2016-12-01
MX2017012293A (es) 2018-01-09
PL3274349T3 (pl) 2020-10-05
CA2977326C (en) 2023-08-29
JP2018509446A (ja) 2018-04-05
KR102606643B1 (ko) 2023-11-28
WO2016151500A1 (en) 2016-09-29
US9802917B2 (en) 2017-10-31
JP6696995B2 (ja) 2020-05-20
ES2803028T3 (es) 2021-01-22
RU2720456C2 (ru) 2020-04-30
RU2017133243A (ru) 2019-04-05
US20160304489A1 (en) 2016-10-20
CN107406448A (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
AU2016238437B2 (en) Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2- oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
JP5845215B2 (ja) 複素環化合物およびその使用
CN108699001B (zh) 作为免疫调节剂的杂环化合物
JP6903580B2 (ja) 乳酸脱水素酵素の小分子阻害剤及びその使用方法
US7304059B2 (en) Substituted quinazolin-4-ylamine analogues
TWI648274B (zh) 作為激酶抑制劑之雜環醯胺類 （二）
EP2699551B1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
CN103857288B (zh) 作为激酶抑制剂的氨基-喹啉
TW201726623A (zh) 作為免疫調節劑之雜環化合物
TW200406374A (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
TW201217362A (en) Heteroaryls and uses thereof
MX2013006284A (es) Derivados sustituidos de imidazoquinolina.
BR112017016991B1 (pt) Partículas de n-(5-ciano-4-((2-metóxi-etil)amino)piridin-2-il)-7-formil-6-((4- metil-2-oxopiperazin-1-il)metil)-3,4-di-hidro-1,8-naftiridina-1(2h)-carboxamida, seu uso e seu processo de preparação, aglomerado, e composição farmacêutica
WO2015162584A1 (en) Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide
AU2003205217A1 (en) Substituted quinazolin-4-ylamine analogues as modulators of capsaicin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)